ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,250.50
0.60%
S&P ASX All Technology
3,828.50
0.37%
Brent Oil
76.495
0.00%
US Dollar vs AUD
1.60849
0.00%
Bitcoin
98,354.09
0.15%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. AtriCure Inc (ATRC) Share Price

AtriCure Inc

AtriCure Inc (ATRC)

NASDAQ
32.03
1.63
(5.36%)
Closed 05 January 8:00AM
Delayed by 15 minutes
32.03
0.02
(0.06%)
After Hours: 10:56AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
32.03
Bid
21.50
Offer
33.81
Volume
439,741
30.39 Day's Range 32.04
18.94 52 Week Range 39.045
Market Cap
1.562B
Previous Close
30.40
Open
30.665
Last Trade
5
@
32
Last Trade Time
Financial Volume
US$ 13,677,018
VWAP
31.1024
Average Volume (3m)
491,330
Shares Outstanding
48,753,251
Dividend Yield
-
PE Ratio
-51.27
Earnings Per Share (EPS)
-0.62
Revenue
399.25M
Net Profit
-30.44M

About AtriCure Inc

AtriCure Inc is a innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft T... AtriCure Inc is a innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Website
www.atricure.com
Headquarters
Wilmington, Delaware, USA
Founded
-
AtriCure Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker ATRC. The last closing price for AtriCure was US$30.40. Over the last year, AtriCure shares have traded in a share price range of US$ 18.94 to US$ 39.045.

AtriCure currently has 48,753,251 shares in issue. The market capitalisation of AtriCure is US$1.48 billion. AtriCure has a price to earnings ratio (PE ratio) of -51.27.

Ask ADVFN Intelligence (AI)

ATRC Latest News

More News

AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...

24 December 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

13 December 2024
Edgar (US Regulatory)

AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...

21 November 2024
Business Wire

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

15 November 2024
Edgar (US Regulatory)

AtriCure to Participate in the Stifel 2024 Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...

08 November 2024
Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

31 October 2024
Edgar (US Regulatory)

Form 8-K - Current report

30 October 2024
Edgar (US Regulatory)

AtriCure Reports Third Quarter 2024 Financial Results

Worldwide revenue of $115.9 million – an increase of 17.9% year over year U.S. revenue of $95.5 million – an increase of 16.8% year over year Achieved 20% growth on revenues from open appendage...

30 October 2024
Business Wire

AtriCure to Participate in the UBS Global Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...

28 October 2024
Business Wire

AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...

15 October 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.44.5706823375830.6332.0329.827709330.44483502CS
4-2.33-6.7811408614734.3634.7929.5635370331.49126298CS
125.0218.585708996727.0138.3426.9249133033.01553058CS
269.5242.292314526922.5138.3420.261725927.5209287CS
52-3.04-8.6683775306535.0739.04518.9468233027.49544115CS
156-37.97-54.24285714297072.3118.9443771235.99740208CS
260-0.64-1.9589837771732.6789.1818.9440414442.22766794CS

ATRC - Frequently Asked Questions (FAQ)

What is the current AtriCure share price?
The current share price of AtriCure is US$ 32.03
How many AtriCure shares are in issue?
AtriCure has 48,753,251 shares in issue
What is the market cap of AtriCure?
The market capitalisation of AtriCure is USD 1.48B
What is the 1 year trading range for AtriCure share price?
AtriCure has traded in the range of US$ 18.94 to US$ 39.045 during the past year
What is the PE ratio of AtriCure?
The price to earnings ratio of AtriCure is -51.27
What is the cash to sales ratio of AtriCure?
The cash to sales ratio of AtriCure is 3.91
What is the reporting currency for AtriCure?
AtriCure reports financial results in USD
What is the latest annual turnover for AtriCure?
The latest annual turnover of AtriCure is USD 399.25M
What is the latest annual profit for AtriCure?
The latest annual profit of AtriCure is USD -30.44M
What is the registered address of AtriCure?
The registered address for AtriCure is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
What is the AtriCure website address?
The website address for AtriCure is www.atricure.com
Which industry sector does AtriCure operate in?
AtriCure operates in the SURGICAL,MED INSTR,APPARATUS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
FCUVFocus Universal Inc
US$ 0.9499
(174.93%)
259.78M
NITON2OFF Inc
US$ 2.6306
(145.85%)
350.92M
CRNCCerence Inc
US$ 19.33
(143.76%)
159.55M
KITTNauticus Robotics Inc
US$ 3.8249
(140.56%)
104.78M
ACONAclarion Inc
US$ 0.2984
(110.14%)
305.59M
HWHHWH International Inc
US$ 0.4621
(-28.80%)
7.08M
SMSTDefiance Daily Target 2x Short MSTR ETF
US$ 5.69
(-26.30%)
24.62M
RAINRain Enhancement Technologies Holdco Inc
US$ 5.59
(-23.42%)
155.16k
PTLEPTL Ltd
US$ 9.35
(-23.30%)
967.95k
NXUNXU Inc
US$ 0.725868
(-22.78%)
7.4M
NITON2OFF Inc
US$ 2.6306
(145.85%)
350.92M
TGLTreasure Global Inc
US$ 0.382
(101.58%)
330.82M
ACONAclarion Inc
US$ 0.2984
(110.14%)
305.59M
FCUVFocus Universal Inc
US$ 0.9499
(174.93%)
259.78M
NVDANVIDIA Corporation
US$ 144.47
(4.45%)
222.72M

ATRC Discussion

View Posts
mlkrborn mlkrborn 11 years ago
HISTORY
Initial Public Offering



On August 10, 2005, we consummated an initial public offering of 4.6 million shares of our common stock at $12.00 per share, which includes the underwriters exercise of their over-allotment option, on August 9, 2005, to purchase 600,000 shares of our common stock of which 450,000 shares were sold by selling shareholders and 150,000 shares were sold by us. We did not receive any proceeds from the sale of the 450,000 shares of common stock that were sold by selling shareholders. These share amounts reflect a 1-for-3.8 reverse split of our capital stock that was effected on July 27, 2005. Proceeds to us from the offering, after deducting underwriting discounts and commissions but before expenses, were $46.3 million. Expenses are estimated to be approximately $3.25 million.



15
👍️0
mlkrborn mlkrborn 11 years ago
AtriCure receives FDA approval for investigational study to evaluate stroke prevention in atrial fibrillation (ATRC) 14.35 : Co announces the FDA approval to begin enrollment in a clinical study of AtriCure's AtriClip Left Atrial Appendage Exclusion System. The study will evaluate the use of the AtriClip device to prevent stroke in patients with Afib. The feasibility study will enroll Afib patients at seven medical centers across the country. The study will focus on patients with risk factors that place them at significant risk of stroke as well as substantial bleeding risks that contraindicate them for anticoagulation therapy. Research suggests that up to 40% of patients are unable to take oral anticoagulants due to excessive risk of bleeding.
👍️0
dmarkg dmarkg 12 years ago
Hey Wobblenuts and Jackie Scan I want to show you something....

Medical Breakthrough Wound Stasis Technology

ATRC and EPGL could possibly go hand in hand here...
Merry Christmas 2012

Merry Chirstmas 2012, friends.
👍️0
wobblenuts wobblenuts 12 years ago
Any talks involving ATRC and soon to be sub penny wonder EPGL?



Are they hinting at something here?


1)"ATRC fully SEC reporting financials are available at OTCMARKETS for EPGL investors to see as an example of where EPGL management is headed."

2)"EPGL initiating R&D on 4 new medical devices before end of 2012."

3)"Property and equipment, net 0"
👍️0
Penny Roger$ Penny Roger$ 13 years ago
~ Monday! $ATRC ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $ATRC ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=ATRC&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=ATRC&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=ATRC
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=ATRC#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=ATRC+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=ATRC
Finviz: http://finviz.com/quote.ashx?t=ATRC
~ BusyStock: http://busystock.com/i.php?s=ATRC&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=ATRC >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.
👍️0
Penny Roger$ Penny Roger$ 13 years ago
AtriCure, Inc., is a medical device company. The Company develops, manufactures and sells cardiac surgical ablation systems designed to create lesions, or scars, in cardiac, or heart, tissue and devices for the exclusion of the left atrial appendage. The Company has two primary product lines for the ablation of cardiac tissue. Its primary product line, which accounts for a majority of its revenues, is Isolator Synergy bipolar ablation clamp system (Isolator system) and related radiofrequency ablation devices. It also offers a cryoablation product line, which features reusable and disposable cryoablation devices. In addition, it offers the AtriClip Gillinov-Cosgrove Left Atrial Appendage System, or AtriClip system, which is designed to exclude the left atrial appendage.

http://www.google.com/finance?q=ATRC
👍️0

Your Recent History

NASDAQ
ATRC
AtriCure
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads